0 patents currently held, every record listed here

4 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

This portfolio holds none of the 4 US patents in force on its record. from the record

Of the 4 now held by other companies, 4 name Oncotherapy Science Inc. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

none

Next term end

When these terms end

Each bar runs from grant to computed term end. 2012 to 2030.

US 8,378,081 Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof Apr 22, 2029

US 9,090,680 Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof Jan 20, 2030

US 8,333,967 Anti-Aß Oligomer Humanized Antibody Sep 22, 2030

US 9,181,332 Anti-A(BETA) Oligomer Humanized Antibody Sep 22, 2030

20162020202420282030

Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

None of the currently held patents qualifies as notable.

Formerly held, still cited

Notable

Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof US 8,378,081

The most cited patent in this portfolio, cited by 32 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2029.

now held by Oncotherapy Science, Inc.

Ends Apr 2029 · High confidence

Also notable

Anti-Aß Oligomer Humanized Antibody US 8,333,967

Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2030.

now held by Oncotherapy Science, Inc.

Ends Sep 2030 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

1 term has ended since Aug 16, 2026

Patents held now

Soonest term end first.

Also on record: 4 patents in force now held by others · 3 patents ended · 3 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Immunas Pharma, Inc.